{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:13:40Z","timestamp":1791764020641,"version":"4.3.4"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2023,3,1]]},"abstract":"<jats:sec id=\"ab-eoi220090-4\"><jats:title>Importance<\/jats:title><jats:p>Prior retrospective studies have provided limited evidence on disease progression following drug cessation in patients with maculopathy associated with pentosan polysulfate (PPS).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220090-5\"><jats:title>Objective<\/jats:title><jats:p>To evaluate the 2-year evolution of maculopathy associated with PPS use after drug cessation.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220090-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This cohort study prospectively evaluated the natural history of patients with maculopathy associated with PPS use. Participants seen at the Emory Eye Center were enrolled between December 1, 2018, and December 1, 2019, and data were collected through November 30, 2021.<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220090-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The main outcomes were changes in visual function and structure. Visual function was assessed annually with refraction and Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA), mesopic microperimetry, and dark adaptometry. Structural outcomes included presence and extent of complete retinal pigment epithelium and outer retinal atrophy (cRORA), macular central subfield thickness (CST), and subfoveal choroidal thickness (SFCT).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220090-8\"><jats:title>Results<\/jats:title><jats:p>Of the 12 participants (23 eyes), 11 (91.7%) were female (1 [8.3%] male), 11 (91.7%) were White (1 [8.3%] Black), and median (IQR) age at enrollment was 58 (47-64) years. Median (IQR) time from PPS discontinuation to initial visit was 0.6 (0.4-1.9) years. Median baseline ETDRS BCVA letter score was 83 (Snellen equivalent, 20\/20) (IQR, 80-86.5 [20\/25-20\/20]), with a median 2-year change of \u22123 (IQR, \u22126 to \u22120.5; <jats:italic>P<\/jats:italic>\u2009=\u2009.08). Four eyes (17.4%) had a letter score decline of 15 or more, all associated with progressive cRORA. Median change in microperimetry average threshold was \u22123.5 dB (IQR, \u22124.1 to \u22122.5 dB; <jats:italic>P<\/jats:italic>\u2009=\u2009.001), and percent reduced threshold was 32.5% (IQR, 20.3%-52.8%; <jats:italic>P<\/jats:italic>\u2009=\u2009.004). Nine eyes (39%) had macular cRORA at baseline, with a median linearized growth rate of 0.23 mm\/y (IQR, 0.22-0.25 mm\/y). Two eyes (8.7%) without atrophy at baseline developed new-onset cRORA. Median baseline CST was 284 \u03bcm (IQR, 253-291 \u03bcm), with a median 2-year change of \u22125 \u03bcm (IQR, \u221213 to 0.5 \u03bcm; <jats:italic>P<\/jats:italic>\u2009=\u2009.0497). Median 2-year change in SFCT was 1 \u03bcm (IQR, \u221218 to 16 \u03bcm; <jats:italic>P<\/jats:italic>\u2009=\u2009.91).<\/jats:p><\/jats:sec><jats:sec id=\"ab-eoi220090-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The findings of this cohort study suggest that functional and structural deficits continue to progress in PPS-associated maculopathy even after drug cessation. Additional study is needed to determine whether these findings can be generalized to other patients with PPS-associated maculopathy and whether longer follow-up could determine subsequent disease course.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2022.6093","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T16:05:34Z","timestamp":1675353934000},"page":"260","source":"Crossref","is-referenced-by-count":22,"title":["Two-Year Outcomes After Variable Duration of Drug Cessation in Patients With Maculopathy Associated With Pentosan Polysulfate Use"],"prefix":"10.1001","volume":"141","author":[{"given":"Emily H.","family":"Jung","sequence":"first","affiliation":[{"name":"Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Lindeke-Myers","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieraj","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"eoi220090r1","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1016\/j.ophtha.2018.04.026","article-title":"Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium.","volume":"125","author":"Pearce","year":"2018","journal-title":"Ophthalmology"},{"issue":"8","key":"eoi220090r2","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1001\/jamaophthalmol.2020.2349","article-title":"Disease course in patients with pentosan polysulfate sodium-associated maculopathy after drug cessation.","volume":"138","author":"Shah","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"eoi220090r3","doi-asserted-by":"publisher","first-page":"656","DOI":"10.3928\/23258160-20191009-10","article-title":"Progressive maculopathy after discontinuation of pentosan polysulfate sodium.","volume":"50","author":"Huckfeldt","year":"2019","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"13","key":"eoi220090r4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1167\/iovs.61.13.33","article-title":"Visual function in pentosan polysulfate sodium maculopathy.","volume":"61","author":"Lyons","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"eoi220090r5","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1001\/jamaophthalmol.2019.3392","article-title":"Phenotypic spectrum of pentosan polysulfate sodium-associated maculopathy: a multicenter study.","volume":"137","author":"Hanif","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"eoi220090r6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1001\/jamaophthalmol.2013.572","article-title":"Square root transformation of geographic atrophy area measurements to eliminate dependence of growth rates on baseline lesion measurements: a reanalysis of age-Related Eye Disease Study Report No. 26.","volume":"131","author":"Feuer","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"eoi220090r7","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ophtha.2019.04.024","article-title":"Strength of association between pentosan polysulfate and a novel maculopathy.","volume":"126","author":"Hanif","year":"2019","journal-title":"Ophthalmology"},{"issue":"3","key":"eoi220090r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100173","article-title":"Longitudinal evaluation of visual function impairments in early and intermediate age-related macular degeneration patients.","volume":"2","author":"Lad","year":"2022","journal-title":"Ophthalmol Sci"},{"issue":"4","key":"eoi220090r9","doi-asserted-by":"publisher","first-page":"AMD195","DOI":"10.1167\/iovs.18-24238","article-title":"Maximum reading speed in patients with geographic atrophy secondary to age-related macular degeneration.","volume":"59","author":"Varma","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"eoi220090r10","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12886-020-01683-8","article-title":"An exploratory study to evaluate visual function endpoints in non-advanced age-related macular degeneration.","volume":"20","author":"Narayanan","year":"2020","journal-title":"BMC Ophthalmol"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2801006\/jamaophthalmology_jung_2023_oi_220090_1678899621.99182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T15:01:56Z","timestamp":1678978916000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2801006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,1]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.6093","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,1]]}}}